# Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

> **NCT00288431** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Cancer
- Sarcoma

## Interventions

- **DRUG:** ridaforolimus
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00288431
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288431, "Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00288431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*